[Federal Register Volume 87, Number 120 (Thursday, June 23, 2022)]
[Notices]
[Page 37521]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-13418]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Charter Renewal

    In accordance with Title 41 of the U.S. Code of Federal 
Regulations, Section 102-3.65(a), notice is hereby given that the 
Charter for the National Cancer Institute Clinical Trials and 
Translational Research Advisory Committee, was renewed for an 
additional two-year period on April 14, 2022.
    It is determined that the National Cancer Institute Clinical Trials 
and Translational Research Advisory Committee, is in the public 
interest in connection with the performance of duties imposed on the 
National Cancer Institute by law, and that these duties can best be 
performed through the advice and counsel of this group.
    Inquiries may be directed to Claire Harris, Director, Office of 
Federal Advisory Committee Policy, Office of the Director, National 
Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda, 
Maryland 20892 (Mail code 4875), Telephone (301) 496-2123, or 
[email protected].

    Dated: June 17, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-13418 Filed 6-22-22; 8:45 am]
BILLING CODE 4140-01-P